Treatment of obstetric and gynecologic infections, with an emphasis on beta-lactamase-producing organisms.
The ideal pharmaceutical treatment for pelvic infections in women should provide good antibacterial coverage, have proven efficacy and be associated with a good outcome in terms of fertility and organ preservation. In an open study, ticarcillin disodium/clavulanate potassium was used to treat upper genital tract infections in 91 women. The clinical success rate was 92% with outpatient-acquired pelvic inflammatory disease; 50% with tuboovarian abscess, as confirmed by ultrasound; 85% with postpartum endometritis; 88% with endometritis plus chorioamnionitis; and 90% with postoperative infection, including cesarean section. The primary adverse reaction was diarrhea, in ten patients. Among the 129 aerobes isolated, 18 (14%) were beta-lactamase positive, as were 32% (20/63) of the anaerobes.
McGregor
J A
JA
Department of Obstetrics, Gynecology, and Infectious Diseases, University of Colorado Health Sciences Center, Denver 80262.
Christiansen
F B
FB
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004716:Endometritis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D010406:Penicillins / Q000627:therapeutic use*; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy*; D012488:Salpingitis / Q000188:drug therapy*; D013982:Ticarcillin / Q000627:therapeutic use*; D065093:beta-Lactamase Inhibitors
D002969:Clavulanic Acids; D004338:Drug Combinations; D010406:Penicillins; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D013982:Ticarcillin